oblimersen sodium

Phase 3RNA therapy

oblimersen sodium is a rna therapy that works as a Bcl-2 MRNA Antisense Inhibitor.[2] It is being investigated across 22 indications, with its most advanced program in Phase 3.[1]

oblimersen sodium is one of 578 biologic programs targeting Merkel cell skin cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

577

Competitors

Pipeline

Status by Indication[3][1]

Indication

Merkel Cell Skin CancerActive, not recruiting

MacroglobulinemiaActive, not recruiting

LymphomaActive, not recruiting

Cutaneous MelanomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Kidney DiseaseActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Merkel Cell Skin CancerPhase 2

Active, not recruiting

MacroglobulinemiaPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Cutaneous MelanomaPhase 3

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPreclinical

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2/Phase 3

Active, not recruiting

Showing 10 of 22 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

oblimersen sodium

NNational Cancer Institute (NCI)

Phase 3

1 2

Halaven

Eisai

Preclinical

38 3

Prolia

Amgen

Preclinical

14 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

MS Contin

Merck & Co.

Preclinical

2 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma5 trials

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00060112·15 enrolled

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054639·48 enrolled

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00086944·25 enrolled

Show 2 more trials

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00080847·160 enrolled

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00301795·52 enrolled

Small Cell Lung Cancer3 trials

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00042978·55 enrolled

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00005032·12 enrolled

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00017251·12 enrolled

Acute Myeloid Leukemia3 trials

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Completed·GGenta Incorporated·Phase 2·NCT00017589

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00085124·500 enrolled

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00039117·32 enrolled

Colorectal Cancer2 trials

Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT00004870

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT00055822·16 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed·BBritish Columbia Cancer Agency·Phase 1·NCT00070083

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated·UUniversity of Nebraska·Phase 1·NCT00736450·37 enrolled

17 more indications

Melanoma2 trials

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Unknown status·JJonsson Comprehensive Cancer Center·N/A·NCT00070343

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Completed·GGenta Incorporated·Phase 3·NCT00016263

Multiple Myeloma2 trials

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00049374

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·GGenta Incorporated·Phase 3·NCT00017602

Breast Cancer1 trial

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00063934·31 enrolled

Refractory Solid Tumors1 trial

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00039481·15 enrolled

Merkel Cell Carcinoma1 trial

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00079131·37 enrolled

Macroglobulinemia1 trial

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00062244·58 enrolled

Patients With Solid Tumors1 trial

Chemotherapy in Treating Patients With Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003103·57 enrolled

Patients With Advanced Solid Tumors1 trial

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00054548·55 enrolled

Gastrointestinal Stromal Tumor1 trial

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00091078·96 enrolled

Chronic Myelogenous Leukemia1 trial

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00049192·43 enrolled

Acute Lymphoblastic Leukemia1 trial

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004862·24 enrolled

Adenocarcinoma1 trial

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00085228·116 enrolled

Metastatic Renal Cell Cancer1 trial

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00059813·41 enrolled

Hepatocellular Carcinoma1 trial

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00047229·27 enrolled

Non-Small Cell Lung Cancer1 trial

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Unknown status·GGenta Incorporated·Phase 2/3·NCT00030641

Chronic Lymphocytic Leukemia1 trial

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed·GGenta Incorporated·Phase 3·NCT00024440

Fluorouracil1 trial

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00064259·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for oblimersen sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — oblimersen sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for oblimersen sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bcl-2 MRNA Antisense Inhibitor[2]
Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

oblimersen sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma5 trials

Small Cell Lung Cancer3 trials

Acute Myeloid Leukemia3 trials

Colorectal Cancer2 trials

Diffuse Large B-Cell Lymphoma2 trials

Melanoma2 trials

Multiple Myeloma2 trials

Breast Cancer1 trial

Refractory Solid Tumors1 trial

Merkel Cell Carcinoma1 trial

Macroglobulinemia1 trial

Patients With Solid Tumors1 trial

Patients With Advanced Solid Tumors1 trial

Gastrointestinal Stromal Tumor1 trial

Chronic Myelogenous Leukemia1 trial

Acute Lymphoblastic Leukemia1 trial

Adenocarcinoma1 trial

Metastatic Renal Cell Cancer1 trial

Hepatocellular Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

Fluorouracil1 trial

References

Drug Info

Quick Facts

Related News